Atlas Trials

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Clinical trial NCT03493451 · COMPLETED

Trial details

NCT number
NCT03493451
Sponsor
BeiGene
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Peripheral T Cell LymphomaPTCLExtranodal NK/T-cell LymphomaExtranodal NK/T-cell Lymphoma, Nasal TypeExtranodal NK T Cell LymphomaExtranodal NK T Cell Lymphoma, NasalAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaAngioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma RefractoryPeripheral T-cell Lymphoma NOSPeripheral T-Cell Lymphoma, Not Otherwise Specified
Start date
2018-04-13
Primary completion
2021-04-21
Enrollment
77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.